- Case report
- Open Access
Fatal myocarditis-associated Bartonella quintana endocarditis: a case report
© Montcriol et al; licensee Cases Network Ltd. 2009
- Received: 18 March 2008
- Accepted: 22 January 2009
- Published: 17 July 2009
Bartonella spp. infection is not rare and must be considered with great care in patients with suspected infective endocarditis, particularly if regular blood cultures remain sterile. Management of these infections requires knowledge of the identification and treatment of these bacteria.
A 50-year-old Senegalese man was admitted to our Department of Cardiac Surgery with a culture-negative endocarditis. Despite valvular surgery and adequate antibiotic treatment, recurrence of the endocarditis was observed on the prosthetic mitral valve. Heart failure required circulatory support. Weaning off the circulatory support could not be attempted owing to the absence of heart recovery. Bacteriological diagnosis of Bartonella quintana endocarditis was performed by molecular methods retrospectively after the death of the patient.
This case report underlines the severity and difficulty of the diagnosis of Bartonella quintana endocarditis. The clinical picture suggested possible Bartonella quintana associated myocarditis, a feature that should be considered in new cases.
- Infective Endocarditis
- Left Ventricle Ejection Fraction
- Systolic Pulmonary Arterial Pressure
- Fulminant Myocarditis
Bartonella quintana is a Gram-negative bacterium first identified as the cause of louse-borne epidemic trench fever in Europe during World War One. Additional manifestations of B. quintana infection including endocarditis, bacillary angiomatosis, chronic bacteremia and pericarditis have been reported . B. quintana infection is an important cause of culture-negative endocarditis . We report a patient with B. quintana endocarditis followed by a myocardial dysfunction which may evoke fulminant myocarditis.
A 50-year-old Senegalese man was hospitalized for a 6-month history of dyspnea, fever and 7 kg weight loss. His past medical history was significant for a myocardial infarction 4 years earlier. No valvulopathy was reported. He testified to good living conditions in Senegal and denied homelessness and substantial alcohol use.
On initial admission to the surgical intensive care unit, his hemodynamic status was stable with blood pressure at 130/60 mmHg with epinephrine 0.8 mg/hour and dobutamine 12 µg/kg/minute. Weaning from the mechanical ventilation was successful at the 6th postoperative hour. Progressively, a right ventricle failure appeared (right ventricle hypokinesia, SPAP of 45 mmHg at echocardiography) with renal and hepatic dysfunction (oliguria, blood urea nitrogen level of 10 mmol/L, creatinine level of 183 µmol/L, alanine aminotransferase (ALAT) level of 20 IU/L, aspartate aminotransferase (ASAT) level of 309 IU/L, bilirubin level of 40 mg/dL) and a troponin Ic level of 159 IU/L on the second postoperative day. Thereafter, cardiogenic shock was observed. Serial cardiac enzymes were consistent with major myocardial injury (troponin Ic >500 IU/L). Right heart catheterization confirmed myocardial dysfunction (pulmonary artery occlusion pressure 25 mmHg, cardiac index 1.5 L/min/m2). Thus, extracorporeal membrane oxygenation (ECMO) with a cardio-pulmonary bypass was set up as a bridge to heart recovery. Despite circulatory support, inhaled nitric oxide and continuous veno-venous hemodiafiltration, hemodynamic status remained precarious (blood pressure at 90/40 mmHg with epinephrine 3.5 mg/hour and dobutamine 10 µg/kg/minute). Echocardiography showed a LVEF of 35%, low left and right filling pressures, and good function of the prosthetic valves without any regurgitation.
During these 10 days, all blood cultures remained negative. Microbiologic examination of the excised valves showed no organism on Gram stain and no bacteriological growth. Microimmunofluorescence serologies performed on two samples of serum drawn on day 1 and on day 8 remained negative for Bartonella spp. (Immunoglobulin G titer <1:100), Coxiella spp., Chlamydia spp., Mycoplasma spp., Legionella spp. and Bosea vestrii. The Western immunoblotting profile suggested a Bartonella spp. endocarditis. On the mitral resected cardiac valve, a broad range polymerase chain reaction (PCR) targeting the 16S ribosomal RNA gene identified a Bartonella quintana endocarditis and species-specific PCR amplification targeting the 16S-23S ribosomal DNA intergenic spacer region gene of Bartonella quintana confirmed this diagnosis. Thirty days after admission to the surgical intensive care unit, Bartonella quintana grew in a blood culture. However, those results were obtained after the death of the patient. Permission for an autopsy was refused.
In developed countries, B. quintana endocarditis is confined to specific groups, for example, body-louse infected, alcoholic, homeless and HIV-infected individuals. In France, Bartonella spp. account for 3% to 4% of infective endocarditis . A north to south gradient in the distribution of this infection has been reported. Africa is still considered to be endemic for B. quintana infections [4, 5]. Our patient was Senegalese and lived in Dakar but had no other known risk factors for B. quintana infections.
Most reported cases of B. quintana endocarditis have affected native valves. Few cases of prosthetic valve endocarditis have been reported -. We report the first case of native valve endocarditis followed by immediate recurrence on a bioprosthetic valve despite adequate antibiotic treatment. We did not observe rapid progression of valvular stenosis as has been described but the rapid development of large vegetation .
The cardiac failure and troponin level that we observed were consistent with major myocardial dysfunction. This dysfunction was probably not a complication of the cardiopulmonary bypass usually observed no more than several hours after the surgery. Furthermore, vasopressor requirement was very low in the first postoperative hours. The patient's hemodynamic profile did not suggest septic shock. Thus, we assumed that this dysfunction was due to a direct infection of the myocardium as can be seen in fulminant myocarditis. Bartonella henselae myocarditis affecting humans has been reported  and a direct infection of myocardial tissue due to B. quintana was suspected in a case report . However, in our patient, a biopsy of the myocardium or post-mortem examination was not carried out. Myocarditis could not be confirmed. If B. quintana myocardial infection could be proved, it would argue in favor of an aggressive treatment of B. quintana induced cardiac failure associating inotropic support and circulatory support until heart recovery.
As we observed, bacteriological diagnosis is difficult and often retrospective. Indeed Bartonella spp. are fastidious growing bacteria. Blood or resected valve cultures remain negative for at least 10 days. In the case of blood culture-negative endocarditis, the first screening must include at least Bartonella spp. and C. burnetii serologies. Usually microimmunofluorescence serology has a high predictive value for the diagnosis of Bartonella spp. endocarditis if a cut-off value of 1:800 for Bartonella spp. Immunoglobulin G titer is used . In very few cases, as in this report, this technique fails to achieve a diagnosis . Western immunoblotting is usually more sensitive than microimmunofluorescence and allows a specific Bartonella species diagnosis when coupled with cross-adsorption . In our patient, the western immunoblotting profile suggested a Bartonella spp. endocarditis. Cross-adsorption was not realized because this technique required a large amount of antigens and the species identification was already established by two different PCR assays performed on the cardiac valve sample. In the case of negative serologies, broad-range PCR followed by sequencing performed on cardiac valve samples could help in the etiological diagnosis as this molecular technique allows the detection of numerous bacterial agents. In the case of positive broad-range PCR, species specific PCR should be applied to confirm the diagnosis. The usefulness of molecular techniques in blood is still debated. But their development would be helpful in guiding initial therapy in patients who do not undergo emergency valvular surgery .
B. quintana endocarditis treatment is non-specific. As in our patient, the delay in diagnosis may provoke serious valve destruction requiring its replacement. More than 90% of patients with B. quintana endocarditis require cardiac surgery . Bartonella spp. are susceptible in vitro to a wide range of agents including penicillins, cephalosporins, aminoglycosides, chloramphenicol, tetracyclines, macrolides, rifampicin, fluoroquinolones and cotrimoxazole. However, aminoglycosides are currently the only known antibiotic class bactericide for Bartonella spp. . Patients treated with aminoglycosides for more than 14 days are more likely to survive than those under therapy for a shorter duration . That is the reason why culture-negative endocarditis treatment should associate α-lactamins for 6 weeks and gentamicin intravenously for 2 weeks . In this case report, the choice of ceftriaxone, recommended by the American Heart Association, would probably not have changed the prognosis because it has no more bactericidal activity on Bartonella spp. than amoxicillin . If Bartonella spp. endocarditis had been suspected, doxycycline could have been added . Given the organ dysfunctions, the persistent sepsis and the disseminated septic emboli, a heart transplant was rejected. This patient died of cardiac failure. Despite adequate antibiotic treatment and valvular surgery, the mortality rate of B. quintana endocarditis remains about 12% .
Bartonella spp. infection is not rare and must be considered with great care in the case of patients with suspected infective endocarditis, particularly if regular blood cultures remain sterile despite absence of antibiotic treatment. African origin should be considered by itself as a risk factor for Bartonella infection. Owing to the high death rate and the difficult diagnosis, culture-negative endocarditis should include aminoglycoside therapy, the only antibiotic treatment bactericide for Bartonella spp., for at least 14 days.
The cardiac failure we observed may evoke fulminant myocarditis. Myocardial biopsy could be decisive to determine whether Bartonella quintana should be included among the myocarditis infectious agents.
Written informed consent was obtained from the patient's next-of-kin for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
We acknowledge Pr F Kerbaul for his help.
- Levy PY, Fournier PE, Carta M, Raoult D: Pericardial effusion in a homeless man due to Bartonella quintana. J Clin Microbiol. 2003, 41: 5291-5293. 10.1128/JCM.41.11.5291-5293.2003.View ArticlePubMedPubMed CentralGoogle Scholar
- Brouqui P, Raoult D: New insight into the diagnosis of fastidious bacterial endocarditis. FEMS Immunol Med Microbiol. 2006, 47: 1-13. 10.1111/j.1574-695X.2006.00054.x.View ArticlePubMedGoogle Scholar
- Houpikian P, Raoult D: Blood culture-negative endocarditis in a reference center: etiologic diagnosis of 348 cases. Medicine (Baltimore). 2005, 84: 162-173. 10.1097/01.md.0000165658.82869.17.View ArticleGoogle Scholar
- Benslimani A, Fenollar F, Lepidi H, Raoult D: Bacterial zoonoses and infective endocarditis, Algeria. Emerg Infect Dis. 2005, 11: 216-224.View ArticlePubMedPubMed CentralGoogle Scholar
- Thiam M, Fall PD, Gning SB, Grinda JM, Mainardi JL: [Bartonella Quintana infective endocarditis in an immunocompetent Senegalese man]. Rev Med Interne. 2002, 23: 1035-1037. 10.1016/S0248-8663(02)00734-8.View ArticlePubMedGoogle Scholar
- Klein JL, Nair SK, Harrison TG, Hunt I, Fry NK, Friedland JS: Prosthetic valve endocarditis caused by Bartonella quintana. Emerg Infect Dis. 2002, 8: 202-203. 10.3201/eid0802.010206.View ArticlePubMedPubMed CentralGoogle Scholar
- Kreisel D, Pasque MK, Damiano RJ, Medoff G, Kates A, Kreisel FH, Lawton JS: Bartonella species-induced prosthetic valve endocarditis associated with rapid progression of valvular stenosis. J Thorac Cardiovasc Surg. 2005, 130: 567-568. 10.1016/j.jtcvs.2004.12.035.View ArticlePubMedGoogle Scholar
- Sondermeijer HP, Claas EC, Orendi JM, Tamsma JT: Bartonella quintana prosthetic valve endocarditis detected by blood culture incubation beyond 10 days. Eur J Intern Med. 2006, 17: 441-443. 10.1016/j.ejim.2006.02.022.View ArticlePubMedGoogle Scholar
- Meininger GR, Nadasdy T, Hruban RH, Bollinger RC, Baughman KL, Hare JM: Chronic active myocarditis following acute Bartonella henselae infection (cat scratch disease). Am J Surg Pathol. 2001, 25: 1211-1214. 10.1097/00000478-200109000-00015.View ArticlePubMedGoogle Scholar
- Fournier PE, Mainardi JL, Raoult D: Value of microimmunofluorescence for diagnosis and follow-up of Bartonella endocarditis. Clin Diagn Lab Immunol. 2002, 9: 795-801.PubMedPubMed CentralGoogle Scholar
- Houpikian P, Raoult D: Western immunoblotting for Bartonella endocarditis. Clin Diagn Lab Immunol. 2003, 10: 95-102.PubMedPubMed CentralGoogle Scholar
- Raoult D, Fournier PE, Vandenesch F, Mainardi JL, Eykyn SJ, Nash J, James E, Benoit-Lemercier C, Marrie TJ: Outcome and treatment of Bartonella endocarditis. Arch Intern Med. 2003, 163: 226-230. 10.1001/archinte.163.2.226.View ArticlePubMedGoogle Scholar
- Rolain JM, Brouqui P, Koehler JE, Maguina C, Dolan MJ, Raoult D: Recommendations for treatment of human infections caused by Bartonella species. Antimicrob Agents Chemother. 2004, 48: 1921-1933. 10.1128/AAC.48.6.1921-1933.2004.View ArticlePubMedPubMed CentralGoogle Scholar
- Foucault C, Brouqui P, Raoult D: Bartonella quintana characteristics and clinical management. Emerg Infect Dis. 2006, 12: 217-223.View ArticlePubMedPubMed CentralGoogle Scholar
- Baddour LM, Wilson WR, Bayer AS, Fowler VG, Bolger AF, Levison ME, Ferrieri P, Gerber MA, Tani LY, Gewitz MH, Tong DC, Steckelberg JM, Baltimore RS, Shulman ST, Burns JC, Falace DA, Newburger JW, Pallasch TJ, Takahashi M, Taubert KA: Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation. 2005, 111: e394-e434. 10.1161/CIRCULATIONAHA.105.165564.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.